Shots:

• DCGI has granted a EUA for tocilizumab in India for the treatment of COVID-19 in hospitalized adults who receives systemic corticosteroids and require supplemental oxygen- non-invasive or invasive mechanical ventilation- or ECMO
• Hetero’s Tocira will be marketed by Hetero Healthcare in India & manufactured by Hetero Biologics
• Tocilizumab (400mg/20ml) is the biosimilar referencing Roche’s Actemra/RoActemra and is expected to be available at the end of Sept’21

| Ref: Hetero | Image: Pharma Boardroom